Global Biosimilars Strategic Business Market Report 2016-2022 - Recent Industry Activity, Market Dynamics and Recent Biosimilar Approvals & Pipeline Analysis - Research and Markets

DUBLIN, August 25, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Biosimilars - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.

Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

The report profiles 71 companies including many key and niche players such as

• Amgen Inc. (US)
• Allergan Plc. (Ireland)
• Biocon Ltd. (India)
• Biopartners GmbH (Switzerland)
• Boehringer Ingelheim GmbH (Germany)
• Celltrion Inc. (South Korea)
• Cipla Ltd. (India)
• Cipla BioTec Private Ltd. (India)
• Dr. Reddy's Laboratories Ltd. (India)
• Eli Lilly and Company (US)
• EPIRUS Biopharmaceuticals, Inc. (US)
• Hospira, Inc. (US)
• Intas Biopharmaceuticals Ltd. (India)
• Merck KGaA (Germany)
• Mylan N.V. (US)
• Pfizer Inc. (US)
• Samsung Bioepis Co., Ltd. (Korea)
• Sandoz International GmbH (Germany)
• STADA Arzneimittel AG (Germany)
• Teva Pharmaceutical Industries Ltd. (Israel)

Key Topics Covered:

1. MARKET OVERVIEW
Introduction to Biosimilars
Biosimilars Set to Revolutionize Healthcare Sector
Biosimilars Offer Great Promise despite Challenges
Specific Guidelines for Biosimilars in Various Countries with Year of Publication
List of Approved Biosimilars & Pending Biosimilar Applications in the EU
List of Approved Biosimilars & Pending Biosimilar Applications in the US
List of Approved Biosimilars in South Korea
Biosimilars Find More Growth in Emerging Markets
Comparison of Entry Barriers for Biogenerics in Select Global Markets
Market Drivers
Patent Expiry of Leading Biopharmaceuticals Leads Way for Biosimilars
Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
Cost Containment Measures
Growing Aging Population
Presence of Major Players
Growth Restraints
Uncertain Regulations
High Lead-time
High Manufacturing Costs
Delivery and Commercialization
Automatic Substitution
Other Impediments to Market Acceptance
Strategies to Aid Survival of Companies

2. RECENT BIOSIMILAR APPROVALS AND PIPELINE ANALYSIS
Biosimilar Approvals in 2016, 2015, & 2014
Select Biosimilar Candidates in Late-Stage Pipeline: 2016
Biosimilars in Pipeline for Major Biologic Drugs: 2016
Increasing Collaborations, Licensing Routes and Partnerships
Indian & Chinese Companies to Emerge Strong in Western Markets
Improved Regulatory Framework
European Union Ahead in the Biosimilars Race
Biosimilars Regulatory Agencies in Select Regional Markets
US Passes Act to Create Biosimilars Pathway, Finally

3. MARKET DYNAMICS & TRENDS
Increased Penetration of Biosimilars
Implications for Manufacturers
Efforts to Push Up Biosimilar Adoption
Improvements in Nomenclature and Interchangeability
Contract Manufacturing Favored by Emerging & Major Biosimilar Players
Companies Eye Human Insulin Biosimilars
Monoclonal Antibodies
A Key Growth Segment for Biosimilars
Approved Monoclonal Antibodies for Therapeutic Use: 1986-2014
Biobetters: Potential Industry Challenge?
High Cost of Biologics
Favorable for Biosimilars
Growing Biosimilars Market
A Clear Advantage for Bioseparation Technologies

4. GLOBAL BIOLOGICS MARKET
Global Biopharmaceutical Drug Market
A Primer
US
The Largest Biologics Market Worldwide
Increasing Share of Biotechnological Drugs to Drive Biosimilars Market
Intensifying Consolidation Activity
Recent M&A Activity in the Biologics Industry: 2014 & 2015

5. PRODUCT OVERVIEW
Introduction
Characteristics of Biosimilars
Biological Drugs
Biological Drugs Manufacturing Process
Development Cycle of Biosimilars
Industry Participants

6. PRODUCT APPROVALS/INTRODUCTIONS
Mylan and Biocon Co-develop trastuzumab Biosimilar
EC Approves Remicade Biosimilar Flixabi® Developed by Samsung Bioepis
Samsung's BLA for Remicade Biosimilar Accepted by USFDA
EMA Approves rituximab Biosimilar Developed by Sandoz
EC Approves New Route of Administration for Sandoz's Biosimilar Binocrit
USFDA Approves INFLECTRA, Celltrion's Biosimilar to Remicade
Japanese Ministry Approves Biocon's Biosimilar Insulin Glargine
EMA Accepts Sandoz's MAA for Neulasta Biosimilar
FDA Accepts Amgen's BLA for ABP-501

7. RECENT INDUSTRY ACTIVITY
Alvotech Acquires Baliopharm GmbH
Dr. Reddy's Inks Collaboration Agreement with TR-Pharm
Premier and Oncobiologics Collaborate to Enhance Biosimilars Adoption
Sandoz Acquires Rights to infliximab Biosimilar from Pfizer
Sandoz Enters into Exclusive License Agreement with Kyowa Hakko Kirin
Mylan Enters Into Biosimilars Development Partnership with Momenta Pharmaceuticals
Merck to Bring Biosimilars to Canada through its Agreement with Samsung
EPIRUS Biopharmaceuticals to Expand Biosimilar Pipeline through Acquisition of Bioceros
Pfizer Acquires Hospira
Astrazeneca Enters into JV with Fujifilm Kyowa Kirin Biologics

8. FOCUS ON SELECT MARKET PLAYERS

9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 71 (including Divisions/Subsidiaries 77)

• The United States (15)
• Canada (1)
• Japan (3)
• Europe (25)
• - France (1)
• - Germany (8)
• - The United Kingdom (5)
• - Spain (1)
• - Rest of Europe (10)
• Asia-Pacific (Excluding Japan) (30)
• Latin America (1)
• Middle-East (2)
  

For more information about this report visit http://www.researchandmarkets.com/research/v3z5fs/biosimilars

Related Topics: Biosimilars and Biosuperiors

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com